{"id":"e2f9f340a0e9","type":"article","url":"https://hartvaat.nl/2026/07/30/hfpef-bij-vrouwen-vereist-geslachtsspecifieke-diagnostiek-en-behandelstrategieen/","title":"HFpEF bij vrouwen vereist geslachtsspecifieke diagnostiek en behandelstrategieën","title_en":"Heart Failure with Preserved Ejection Fraction in Women: Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Current cardiology reports","doi":"10.1007/s11886-026-02392-2","source_url":"https://doi.org/10.1007/s11886-026-02392-2","authors":["Sharon Andrade-Bucknor","Shiva Barforoshi","D Elizabeth Le","Radmila Lyubarova","Jina Chung"],"significance":6,"published":"2026-08-16","source_date":"2026-07-30","image":"https://hartvaat.nl/global/img/80e309ecfaf6.webp","kennis":["https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/","https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/"],"congress":"","summary_en":"This narrative review examines sex-specific differences in the pathophysiology, diagnostic challenges, and therapeutic responses of heart failure with preserved ejection fraction (HFpEF) in women. Women face a twofold higher lifetime risk of HFpEF compared to HFrEF, with obesity and microvascular dysfunction playing key roles. Current echocardiographic parameters for assessing diastolic dysfunction and filling pressures may require sex-specific refinements to improve diagnostic accuracy. Enhancing outcomes will depend on greater female representation in cardiovascular trials and further investigation into sex-targeted diagnostic and treatment approaches.","created":"2026-08-09T01:54:39Z","updated":"2026-08-10T10:35:20Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze review belicht de verschillen in pathofysiologie, diagnostiek en behandeling van hartfalen met behouden ejectiefractie (HFpEF) specifiek bij vrouwen. Vrouwen hebben een tweemaal zo hoog levenslang risico op HFpEF vergeleken met HFrEF, waarbij obesitas en microvasculaire dysfunctie een centrale rol spelen. Bestaande echocardiografische parameters voor diastole en vuldrukken blijken mogelijk niet optimaal voor vrouwen, wat de diagnostische nauwkeurigheid kan beïnvloeden. Voor verbeterde uitkomsten is meer deelname van vrouwen aan klinisch onderzoek nodig, evenals verder onderzoek naar vrouw-specifieke behandelstrategieën.","abstract_original":"PURPOSE OF REVIEW: This review highlights differences in pathophysiologic mechanisms, diagnostic challenges and therapeutic responses of heart failure with preserved ejection fraction (HFpEF) in women. RECENT FINDINGS: Emerging research provides further insight into the pathophysiology of HFpEF in women, and the role of obesity and its impact on treatment. Other theories highlight the role of microvascular dysfunction in women with HFpEF. Gender differences in cardiac imaging parameters for assessment of diastolic dysfunction and elevated filling pressures may require refinement for improved diagnostic accuracy of HFpEF in women. HFpEF is fast becoming the dominant form of heart failure in the US and women have double the lifetime risk of developing HFpEF compared with heart failure with reduced ejection fraction. Gender-specific diagnostic parameters and treatment options have been hindered by low participation of women in cardiovascular trials. Increased participation in larger scale trials and further investigations into sex-specific pathophysiology are needed for improved outcomes in women."}